

# Schizophrenia: Advances in Understanding and Treatment

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within topics and years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

## 2016

- Bechtold J, Hipwell A, Lewis DA, et al: Concurrent and sustained cumulative effects of adolescent marijuana use on subclinical psychotic symptoms. *Am J Psychiatry* (Epub ahead of print, May 3, 2016)
- Clementz BA, Sweeney JA, Hamm JP, et al: Identification of distinct psychosis biotypes using brain-based biomarkers. *Am J Psychiatry* 2016; 173:373–384
- Cristóbal-Narváez P, Sheinbaum T, Ballespí S, et al: Impact of adverse childhood experiences on psychotic-like symptoms and stress reactivity in daily life in nonclinical young adults. *PLoS One* 2016; 11:e0153557**
- Heilbronner U, Samara M, Leucht S, et al: The longitudinal course of schizophrenia across the lifespan: clinical, cognitive, and neurobiological aspects. *Harv Rev Psychiatry* 2016; 24:118–128
- Kane JM, Robinson DG, Schooler NR, et al: Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. *Am J Psychiatry* 2016; 173:362–372
- McEvoy J, Citrome L: Brexpiprazole for the treatment of schizophrenia: a review of this novel serotonin-dopamine activity modulator. *Clin Schizophr Relat Psychoses* 2016; 9:177–186
- Tek C, Kucukgoncu S, Guloksuz S, et al: Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. *Early Interv Psychiatry* 2016; 10:193–202**

## 2015

- Connery HS: Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. *Harv Rev Psychiatry* 2015; 23:63–75
- Farrell MS, Werge T, Sklar P, et al: Evaluating historical candidate genes for schizophrenia. *Mol Psychiatry* 2015; 20: 555–562
- Green MF, Horan WP, Lee J: Social cognition in schizophrenia. *Nat Rev Neurosci* 2015; 16:620–631
- Haring L, Koido K, Vasar V, et al: Antipsychotic treatment reduces psychotic symptoms and markers of low-grade

inflammation in first episode psychosis patients, but increases their body mass index. *Schizophr Res* 2015; 169:22–29

- Kane JM, Zukin S, Wang Y, et al: Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. *J Clin Psychopharmacol* 2015; 35:367–373
- Laurens KR, Luo L, Matheson SL, et al: Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. *BMC Psychiatry* 2015; 15:205
- Lee J, Takeuchi H, Fervaha G, et al: Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. *Can J Psychiatry* 2015; 60:515–522**
- Leucht S, Winter-van Rossum I, Heres S, et al: The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. *Schizophr Bull* 2015; 41:549–558**
- McFarlane WR, Levin B, Travis L, et al: Clinical and functional outcomes after 2 years in the Early Detection and Intervention for the Prevention of Psychosis multisite effectiveness trial. *Schizophr Bull* 2015; 41:30–43
- Mueser KT, Penn DL, Addington J, et al: The NAVIGATE program for first-episode psychosis: rationale, overview, and description of psychosocial components. *Psychiatr Serv* 2015; 66:680–690
- Pearlson GD: Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder. *Annu Rev Clin Psychol* 2015; 11:251–281
- Siu CO, Harvey PD, Agid O, et al: Insight and subjective measures of quality of life in chronic schizophrenia. *Schizophr Res Cogn* 2015; 2:127–132

## 2014

- Bentall RP, de Sousa P, Varese F, et al: From adversity to psychosis: pathways and mechanisms from specific adversities to specific symptoms. *Soc Psychiatry Psychiatr Epidemiol* 2014; 49:1011–1022

- Correll CU, Kane JM: Schizophrenia: mechanism of action of current and novel treatments. *J Clin Psychiatry* 2014; 75:347–348
- Keshavan MS, Vinogradov S, Rumsey J, et al: Cognitive training in mental disorders: update and future directions. *Am J Psychiatry* 2014; 171:510–522
- Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 2014; 511:421–427
- Stan AD, Tamminga CA: New options for the treatment of schizophrenia: a clinical review of the three most recent antipsychotic drugs. *Focus* 2014; 12:127–135
- 2013**
- Andreasen NC, Liu D, Ziebell S, et al: Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. *Am J Psychiatry* 2013; 170:609–615
- Driver DI, Gogtay N, Rapoport JL: Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. *Child Adolesc Psychiatr Clin N Am* 2013; 22: 539–555
- Greenwood TA, Swerdlow NR, Gur RE, et al: Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. *Am J Psychiatry* 2013; 170:521–532
- Heckers S, Barch DM, Bustillo J, et al: Structure of the psychotic disorders classification in DSM-5. *Schizophr Res* 2013; 150:11–14**
- Kranzler HN, Cohen SD: Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. *Child Adolesc Psychiatr Clin N Am* 2013; 22: 727–744
- Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013; 382:951–962 (Reprinted in *Focus* 2014; 12:192–204)
- McClellan J, Stock S: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *J Am Acad Child Adolesc Psychiatry* 2013; 52:976–990. [http://www.jaacap.com/article/S0890-8567\(13\)00112-3/pdf](http://www.jaacap.com/article/S0890-8567(13)00112-3/pdf)
- Sikich L: Diagnosis and evaluation of hallucinations and other psychotic symptoms in children and adolescents. *Child Adolesc Psychiatr Clin N Am* 2013; 22:655–673
- FURTHER READING**
- Bechdolf A, Wagner M, Ruhrmann S, et al: Preventing progression to first-episode psychosis in early initial prodromal states. *Br J Psychiatry* 2012; 200:22–29
- Cerimele JM, Durango A: Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. *J Clin Psychiatry* 2012; 73:e1039–e1047
- Clemmensen L, Vernal DL, Steinhausen HC: A systematic review of the long-term outcome of early onset schizophrenia. *BMC Psychiatry* 2012; 12:150
- Kingdon DG, Turkington D: *Cognitive-Behavioral Therapy of Schizophrenia*. New York, Guilford, 1994
- Lencer R, Harris MSH, Weiden PJ, et al: *When Psychopharmacology Is Not Enough: Using Cognitive Behavioral Therapy Techniques for Persons With Persistent Psychosis*. Boston, Hogrefe, 2011
- Stone JM: Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? *Ther Adv Psychopharmacol* 2011; 1:5–18